Cell and Gene Therapy in Parkinson’s Disease Clinical Trials

DelveInsight’s analysis highlights that the Cell and Gene Therapy pipeline for Parkinson’s Disease includes 18+ leading companies actively engaged in developing over 20 therapeutic candidates.

Cell and Gene Therapy in Parkinson’s Disease Overview:

The Parkinson’s Foundation notes that Parkinson’s disease is a neurodegenerative disorder that mainly affects dopamine-producing neurons in the brain’s substantia nigra. Since the disease advances slowly, it is divided into distinct stages to monitor symptom progression and predict future developments. Parkinson’s disease is generally classified into five stages: Stage I through Stage V.

Request for a detailed insights report on Cell and Gene Therapy in Parkinson’s Disease pipeline insights

“Cell and Gene Therapy in Parkinson’s Disease Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Cell and Gene Therapy in Parkinson’s Disease Therapeutics Market.

Key Takeaways from the Cell and Gene Therapy in Parkinson’s Disease Pipeline Report

• DelveInsight’s Cell and Gene Therapy in Parkinson’s Disease pipeline report highlights a dynamic landscape with 18+ companies actively engaged in developing over 20 therapeutic candidates for Parkinson’s treatment. Major players, including Sumitomo Dainippon Pharma, BlueRock Therapeutics, Aspen Neuroscience, Prevail Therapeutics, S.Biomedics, MeiraGTx, Asklepios BioPharmaceutical, Hope Biosciences, and others, are advancing innovative approaches to enhance the treatment paradigm.

• Notable pipeline assets currently under investigation include AB-1005, HB-adMSCs, ANPD 001, BRT-DA01, and several more. In May 2024, the FDA granted RMAT designation to bemdaneprocel, a novel cell therapy aimed at replacing dopamine-producing neurons lost in Parkinson’s disease, recognizing its potential to address significant unmet needs.

• Data shared in March 2024 from a Phase I trial indicated that bemdaneprocel was safe and generally well-tolerated, with the therapy designed to transplant stem cell-derived dopaminergic progenitor cells into the brain’s putamen to restore both motor and non-motor functions.

• Further, in June 2024, the FDA approved iRegene’s IND application for NouvNeu001, marking a milestone as the first chemically induced allogeneic cell therapy for Parkinson’s disease to enter U.S. clinical development. This approval paves the way for clinical trials to assess its safety and efficacy.

Cell and Gene Therapy in Parkinson’s Disease Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Cell and Gene Therapy in Parkinson’s Disease Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cell and Gene Therapy in Parkinson’s Disease treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Cell and Gene Therapy in Parkinson’s Disease market.

Download our free sample page report on Cell and Gene Therapy in Parkinson’s Disease pipeline insights

Cell and Gene Therapy in Parkinson’s Disease Emerging Drugs

• AB-1005 : Asklepios BioPharmaceutical

• HB-adMSCs: Hope Biosciences

• ANPD 001: Aspen Neuroscience

• BRT-DA01: BlueRock Therapeutics

Cell and Gene Therapy in Parkinson’s Disease Companies

Over 18 leading companies are actively engaged in developing cell and gene therapies for Parkinson’s disease. Among these, Asklepios BioPharmaceutical and Hope Biosciences have candidates in the most advanced stage, currently undergoing Phase II clinical trials.

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Cell and Gene Therapy in Parkinson’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Cell and Gene Therapy in Parkinson’s Disease Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Cell and Gene Therapy in Parkinson’s Disease Therapies and Key Companies: Cell and Gene Therapy in Parkinson’s Disease Clinical Trials and advancements

Cell and Gene Therapy in Parkinson’s Disease Pipeline Therapeutic Assessment

• Cell and Gene Therapy in Parkinson’s Disease Assessment by Product Type

• Cell and Gene Therapy in Parkinson’s Disease By Stage

• Cell and Gene Therapy in Parkinson’s Disease Assessment by Route of Administration

• Cell and Gene Therapy in Parkinson’s Disease Assessment by Molecule Type

Download Cell and Gene Therapy in Parkinson’s Disease Sample report to know in detail about the Cell and Gene Therapy in Parkinson’s Disease treatment market @ Cell and Gene Therapy in Parkinson’s Disease Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Cell and Gene Therapy in Parkinson’s Disease Current Treatment Patterns

4. Cell and Gene Therapy in Parkinson’s Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Cell and Gene Therapy in Parkinson’s Disease Late-Stage Products (Phase-III)

7. Cell and Gene Therapy in Parkinson’s Disease Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Cell and Gene Therapy in Parkinson’s Disease Discontinued Products

13. Cell and Gene Therapy in Parkinson’s Disease Product Profiles

14. Cell and Gene Therapy in Parkinson’s Disease Key Companies

15. Cell and Gene Therapy in Parkinson’s Disease Key Products

16. Dormant and Discontinued Products

17. Cell and Gene Therapy in Parkinson’s Disease Unmet Needs

18. Cell and Gene Therapy in Parkinson’s Disease Future Perspectives

19. Cell and Gene Therapy in Parkinson’s Disease Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Cell and Gene Therapy in Parkinson’s Disease Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/